Liquidia Technologies, a Research Triangle Park, North Carolina-based biopharmaceutical company developing particle-based vaccines and therapeutics, has added an additional investor, PPD, Inc., to its Series C financing. PPD, a global contract research organization, joins Canaan Partners, New Enterprise Associates, Morningside Venture Investments Limited, Pappas Ventures and Firelake Capital as investors in the Series C round.
This addition brings the total funding for this round to $25m. The initial Series C closing was announced in January 2010.
The proceeds from the financing will be used to accelerate Liquidia’s lead vaccine candidate through initial clinical studies and expand development of particle-based solutions for novel vaccines and therapeutics.
FinSMEs
20/04/2010